ClinicalTrials.gg
Active, not recruitingNCT07028606RGDUpdated Jun 19, 2025

Vertical Ridge Augmentation Using Computer-guided Sandwich Osteotomy Technique

A Phase 1 interventional study of Sandwich technique with xenograft, collagen membrane and simultaneous implant placement. and Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement. in Alveolar Bone Resorption, sponsored by Al-Azhar University. Active, not recruiting at 1 site in Egypt. Open to participants aged 30 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Al-Azhar University · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled May 2024, registered Apr 2025).
Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
30 Years to 45 Years
Sex
All
01

Study summary

Researcher will introduce the trial to patients and provide full explanation of its aim and benefits in Arabic language. Patients will then be able to have an informed discussion with the researcher. Researcher will obtain written consent from patients willing to participate in the trial

Read the detailed description

This protocol and the template informed consent form will be reviewed by the Ethics Committee of Scientific Research -Faculty of Oral and Dental Medicine- Al-Azhar University.

02

Conditions studied

  • Alveolar Bone Resorption

Browse trials for

03

In context

Bone Resorption

167 studies on the registry are indexed under Bone Resorption; 28 are open to participants now.

This study's planned enrollment of 12 is below the median of 24 across 146 interventional studies indexed under Bone Resorption.

Browse Bone Resorption studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age 30-45) with vertical ridge deficiency.
  • Patients with maxillary vertical ridge deficiency 4-8mm according to Cologne Classification of Alveolar Ridge Defects (CCARD).
  • Patients with good oral hygiene.
  • Free from systemic diseases that may influence the outcome of the therapy.

Exclusion criteria

Exclusion criteria

  • Systemic conditions which are generally considered to be a to implant surgery which included but not limited to: osteoporosis, uncontrolled diabetes.
  • Pregnant or lactating females
  • Current or former smokers.
  • Patient treated by chemotherapy or radio therapy,
  • Allergy to any material or medication used in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Placebo comparator
    Sandwich technique with xenograft, collagen membrane and simultaneous implant placement

    (Control group) will receive computer-guided sandwich osteotomy technique with xenograft, collagen membrane and simultaneous implant placement.

    Procedure: Sandwich technique with xenograft, collagen membrane and simultaneous implant placement.

  • Active comparator
    Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement

    (Study group) will receive computer-guided sandwich osteotomy technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.

    Biological: Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.

Interventions

  • ProcedureSandwich technique with xenograft, collagen membrane and simultaneous implant placement.

    All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft. Osteotomy for implant will be carried out with advanced kit of roott_system Switzerland brand, sandwich osteotomy technique will be carried out with three full thickness cuts using the tungsten carbide disc were performed in the form of two vertical cuts away from the neighboring teeth by 3 mm and one horizontal bony cut on the labial surface of alveolar ridge. Bone splitting chisels were used in sequential width (2 mm, 3 mm) and lightweight mallet to complete splitting of the bony segment, the surgical sites will be irrigated with sterile saline. Surgical flaps will be sutured to the pre-surgical level.

  • BiologicalSandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.

    All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft with and with RGD. Injectable RGD-bioconjugate Mussel Adhesive Proteins (RGD-MAPs) composite hydroxypropyl methylcellulose (HPMC) hydrogels . Previously we developed a novel type of injectable self-supported hydrogel (2 mg/ml of RGD-MAPs/HPMC) based porcine nano hydroxyapatite (MPH) for dental graft, which could good handling property, biodegradation or biocompatibility with the hydrogel disassembly and provided efficient cell adhesion activity and no inflammatory responses. Surgical flaps will be sutured to the pre-surgical level with 4-0 polyproline non resorbable suture utilizing a single interrupted suturing technique.

06

What researchers measure

Primary outcomes

  1. Effect of RGD on volumetric bone changes

    Cone beam computed tomography with minimal field of view was taken immediately after surgery, immediately before loading (6 months) and 6 months after loading to evaluate volumetric changes.

    Time frame: Preoperative Cone beam computed tomography (CBCT) with minimal field of view will be taken for (implant treatment plan), immediately after surgery, at time of loading and 6 months after loading.

07

Study locations

1 site
  • Al-Azhar University, Cairo, Boys
    Cairo, Nasr City 4450113, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07028606
Responsible party
Ahmed Khairy morsi (Assistant Iecturer at Oral Medicine, Periodontology, Oral Radiology and Oral Diagnosis, Faculty of Oral and Dental Medicine, Al-Azhar University, Principal Investigator., Al-Azhar University) — Principal investigator
First posted
Jun 19, 2025
Start date
May 9, 2024
Primary completion
May 10, 2025
Completion
Jun 10, 2025 (estimated)
Last update
Jun 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion